The glycosylation and orientation in the membrane of the third cytoplasmic loop of human P-glycoprotein is affected by mutations and substrates

被引:14
作者
Loo, TW
Clarke, DM
机构
[1] Univ Toronto, Dept Med, MRC, Grp Membrane Biol, Toronto, ON M5S 1A8, Canada
[2] Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada
关键词
D O I
10.1021/bi982525y
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Multiple topologies have been detected for the COOH-terminal half of the human multidrug resistance P-glycoprotein (P-gp), In one topology, the predicted third cytoplasmic loop (CL3) is on the cytoplasmic side (P-gp-CL3-cyt) of the membrane. In an alternate topology, CL3 is on the extracellular side of the membrane (P-gp-CL3-ext). It is not known if both forms of P-gp are active because it is difficult to distinguish either topology in the full-length molecule. When the halves of P-gp are expressed as separate polypeptides, the two topologies of the C-Half are readily distinguished on SDS-PAGE, because only the C-Half (CL3-ext) is glycosylated. To rest whether both topologies can fold into an active enzyme, we assayed for interaction between the N- and C-Halves of P-gp since functional P-gp requires interaction between both halves. In a mutant P-gp (E875C) that gave about equal amounts of both topologies, only the C-Half(CL3-cyt) could be recovered by nickel chromatography after coexpression with the histidine-tagged N-Half P-gp. The isolated N-Half and E875C C-Half (CL3-cyt) polypeptides, when expressed together, exhibited verapamil- and vinblastine-stimulated ATPase activities that were similar to the wild-type enzyme. We also found that biosynthesis of mutant E875C C-Half in the presence of the N-Half P-gp resulted in enhanced expression of C-Half(CL3;cyt). By contrast, interaction of C-Half (CL3-ext) with N-Half P-gp was not detected. These results show that the topology of the C-Half portion of P-gp greatly influences its interactions with the amino-terminal half of the molecule.
引用
收藏
页码:5124 / 5129
页数:6
相关论文
共 34 条
[1]   Relation between the turnover number for vinblastine transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein [J].
Ambudkar, SV ;
Cardarelli, CO ;
Pashinsky, I ;
Stein, WD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (34) :21160-21166
[2]   P-glycoprotein multidrug resistance and cancer [J].
Bosch, I ;
Croop, J .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1996, 1288 (02) :F37-F54
[3]   INTERNAL DUPLICATION AND HOMOLOGY WITH BACTERIAL TRANSPORT PROTEINS IN THE MDR1 (P-GLYCOPROTEIN) GENE FROM MULTIDRUG-RESISTANT HUMAN-CELLS [J].
CHEN, CJ ;
CHIN, JE ;
UEDA, K ;
CLARK, DP ;
PASTAN, I ;
GOTTESMAN, MM ;
RONINSON, IB .
CELL, 1986, 47 (03) :381-389
[4]   Transmembrane orientation of signal-anchor proteins is affected by the folding state but not the size of the N-terminal domain [J].
Denzer, AJ ;
Nabholz, CE ;
Spiess, M .
EMBO JOURNAL, 1995, 14 (24) :6311-6317
[5]   Mechanism involved in generating the carboxyl-terminal half topology of P-glycoprotein [J].
Han, ES ;
Zhang, JT .
BIOCHEMISTRY, 1998, 37 (34) :11996-12004
[6]   PREDICTING THE ORIENTATION OF EUKARYOTIC MEMBRANE-SPANNING PROTEINS [J].
HARTMANN, E ;
RAPOPORT, TA ;
LODISH, HF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (15) :5786-5790
[7]   ABC TRANSPORTERS - FROM MICROORGANISMS TO MAN [J].
HIGGINS, CF .
ANNUAL REVIEW OF CELL BIOLOGY, 1992, 8 :67-113
[8]   MEMBRANE TOPOLOGY OF P-GLYCOPROTEIN AS DETERMINED BY EPITOPE INSERTION - TRANSMEMBRANE ORGANIZATION OF THE N-TERMINAL DOMAIN OF MDR3 [J].
KAST, C ;
CANFIELD, V ;
LEVENSON, R ;
GROS, P .
BIOCHEMISTRY, 1995, 34 (13) :4402-4411
[9]   Transmembrane organization of mouse P-glycoprotein determined by epitope insertion and immunofluorescence [J].
Kast, C ;
Canfield, V ;
Levenson, R ;
Gros, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (16) :9240-9248
[10]   The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors [J].
Kim, RB ;
Fromm, MF ;
Wandel, C ;
Leake, B ;
Wood, AJJ ;
Roden, DM ;
Wilkinson, GR .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (02) :289-294